- Dabrafenib combined with trametinib could be a new treatment for patients with BRAFV600E-mutant NSCLC.
- Phase 2 multicenter, international and non-randomized trial that enrolled 59 patients with pretreated metastatic stage IV BRAFV600E -mutant NSCLC who had progressed after standard treatment.
- Patients received oral dabrafenib (150 mg twice daily) plus oral trametinib (2 mg once daily) in continuous 21-d cycles until disease progression, intolerable toxicity, withdrawal of consent, or death.
- The study is ongoing.
- At 11.6 mo follow-up (interquartile range, 8.8–15.2), 36 (63.2% [95% CI, 49.3–75.6]) patients achieved overall response: 2 (4%) with complete responses and 34 (60%) with partial responses.
- 45 patients (78.9% [95% CI, 66.1–88.6) achieved disease control (complete response + partial response + stable disease).
- Median progression-free survival was 9.7 mo (95% CI, 6.9–19.6); 32 patients had disease progression or died by ...
Access to the full content of this site is available only to registered healthcare professionals. Register to read more